Mycophenolatemofetil Accord (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mycophenolatemofetil Accord, is an antimetabolite presented as an oral formulation for oral use. It is employed to prevent organ transplant rejection and to treat certain autoimmune diseases such as lupus nephritis. GNH USA supplies Mycophenolatemofetil Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil is used in immunosuppressive regimens that target lymphocyte proliferation in transplant and autoimmune settings.

Organ transplant rejection: helps prevent graft rejection in kidney, heart, liver and other transplanted organs. Lupus nephritis: reduces renal inflammation and proteinuria in patients with systemic lupus erythematosus. Other autoimmune diseases: contributes to disease control in conditions such as vasculitis and dermatomyositis.

Adverse reactions may range from mild to severe and should be monitored throughout therapy.

Common Side Effects: - Nausea and vomiting - Diarrhea or loose stools - Abdominal pain or cramping - Headache - Upper respiratory tract infections - Decreased appetite

Serious or Rare Side Effects: - Leukopenia or severe neutropenia - Anemia or thrombocytopenia - Opportunistic infections (e.g., CMV, PCP) - Hepatic dysfunction or elevated transaminases - Malignancies, particularly lymphoproliferative disorders - Teratogenic effects leading to fetal harm

Patients receiving Mycophenolatemofetil should be observed for hematologic and infectious complications, as well as organ‑specific toxicity.

Monitor blood counts: perform regular CBC to detect leukopenia or anemia. Assess liver function: check transaminases and bilirubin periodically. Screen for infections: evaluate for viral, bacterial or fungal infections before and during therapy. Avoid pregnancy: drug is contraindicated in pregnancy (Category X) and effective contraception is required. Vaccination caution: live vaccines should be avoided while on treatment. Store at room temperature below 25°C: keep in the original container, protect from moisture and light.

Mycophenolate Mofetil can interact with several agents that affect its absorption or metabolism.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce drug absorption. - Strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole): increase mycophenolic acid exposure. - Live vaccines: heightened risk of infection.

Moderate Interactions (Monitor Closely): - Azathioprine or other bone‑marrow suppressants: additive hematologic toxicity. - Warfarin: may potentiate anticoagulant effect, requiring INR monitoring. - Non‑live vaccines: monitor immune response effectiveness. - High‑dose steroids: may increase infection risk. - Renal‑impairing drugs: adjust monitoring of renal function.